Innate immune response gene expression profiles characterize primary antiphospholipid syndrome

Genes and Immunity

Volumn 9, Issue 1, 2008, Pages 38-46

  Bernales, I ^a   Fullaondo, A ^a   Marin Vidalled M J ^b   Ucar, E ^c   Martinez Taboada V ^d   Lopez Hoyos M ^b   Zubiaga, A M ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; APRIL PROTEIN; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CD14 ANTIGEN; COMPLEMENT COMPONENT C3; DNA ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; LA ANTIBODY; LIPOPOLYSACCHARIDE; LUPUS ANTICOAGULANT; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SCRAMBLASE; SCRAMBLASE 1; STAT1 PROTEIN; TOLL LIKE RECEPTOR 8; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BINDING SITE; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE ACTIVITY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IN VITRO STUDY; INNATE IMMUNITY; MICROARRAY ANALYSIS; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION; UPREGULATION;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BINDING SITES; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOKINES; E2F4 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, NATURAL; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MIDDLE AGED; TOLL-LIKE RECEPTOR 8; TRANSCRIPTION, GENETIC;

EID: 38549095599     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364443     Document Type: Article

References (42)

1. Yasuda S, Bohgaki M, Atsumi T, Koike T. Pathogenesis of antiphospholipid antibodies: Impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. Immunobiology 2005; 210: 775-780.
2. Mackworth-Young CG. Antiphospholipid syndrome: Multiple mechanisms. Clin Exp Immunol 2004; 136: 393-401.
3. Khamashta MA, Hughes GR. Antiphospholipid antibodies. A marker for thrombosis and recurrent abortion. Clin Rev Allergy 1994; 12 287-296.
4. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizio et al. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214.
5. Alarcon-Segovia D, Sanchez-Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary adiphospholipid syndrome. J Rheumatol 1989; 42: 1309-1311.
6. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J et al. The 'primary' antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-374.
7. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177-186.
8. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
9. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood tells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
10. Rus V, Atamas SP, Shustova V, Luzina IG, Selaru F, Magder LS. et al Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol 2002; 102: 283-290.
11. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R et al. Stotins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 2870-2878.
12. Rasch E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A et al Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500.
13. Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Furasaki A et al The p38 mitogen activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004; 16: 1633-1641.
14. Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB. T cell response in experimental autoimmune encephalomyelitis (EAE): Role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 2002; 20 101-123.
15. Liu Cq, Navratil JS, Sabatine JM, Ahearn JM. Apoptosis, complement and systemic lupus erythematosus: A mechanistic view. Curr Dir Autoimmun 2004; 7: 49-86.
16. *0501+ children with untreated dermatomyositis: A novel model of pathogenesis. J Immunol 2002; 15: 4154-4163.
17. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogrens syndrome. Proc Natl Aca Sci USA 2006; 103: 2770-2775.
18. Potti A, Bild A, Dressman HK, Lewis DA, Nevins JR, Ortel TL. Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood 2006; 107: 1391-1396.
19. Griffin JH, Fernández JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost 2007; 5 (Suppl.1): 73-80.
20. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174: 1259-1268.
21. Sioud M. An overview of the immune system and technical advances in tumor antigen discovery and validation. Trends Mol Med 2005; 12 167-176.
22. Gibbard RJ, Morley PJ, Gay NJ. Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pH-dependent signaling. J Biol Chem 2006; 281: 27503-27511.
23. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
24. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-1573.
25. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202: 1575-1585.
26. Pittoni V, Isenberg D. Apoptosis and antiphospholipid, antibodies. Sem Arthritis Rheum 1998; 28: 163-178.
27. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: Implications for the induction and maintenance of the autoinumme process. Arthritis Rheum 2006; 54: 3601-3611.
28. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309: 1380-1384.
29. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002; 16: 245-256.
30. Murga M, Fernandez-Capetillo O, Field SJ, Moreno B, Borlado LP, Fujiyara Y et al. Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity 2001; 15: 959-970.
31. Garcia I, Murga M, Vicario A, Field SJ, Zubiaga AM. A role for E2F1 in the induction of apoptosis during thymic negative selection. Cell Growth Differ 2000; 11: 91-98.
32. DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim Biophys Acta 2002; 1602: 131-150.
33. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
34. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
35. Wong RCW, Adelstein S, Gillis D, Favaloro EJ. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing, Semin Thromb Hemost 2005; 31: 39-48.
36. Greaves M, Cohen H, MacHin SJ, Mackie I: Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-715.
37. Martin M, Echevarria S, Leyva-Cobiah F, Pereda I, Lopez-Hoyos M. Limited immune reconstitution at intermediate stages of HIV-1 infection during one year of highly active antiretroviral therapy in antiretroviral-naive versus non-naive adults. Eur J Clin Microbiol Infect Dis 2001; 20: 871-879.
38. Iglesias A, Murga M, Laresgoiti U, Skoudy A, Bernales I, Fullaondo A et al. Diabetes and exocrine pancreatic insufficiency in E2F1/E2F2 double-mutant rice. J Clin Invest 2004; 113: 1398-1407.
39. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al. TM4: A free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374-378.
40. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: P3.
41. Hosack DA, Dennis Jr G, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003; 4: R70.
42. Cole SW, Yan W, Galic Z, Arevalo J, Zack JA. Expression-based monitoring of transcription factor activity: The TELiS database. Bioinformatics 2005; 21: 803-810.